Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Global, Open-label Study to Investigate the Efficacy and Safety ofSerpinPC in Subjects With Hemophilia B With Inhibitors
Reding, M. T. (PI)
10/15/24 → 10/14/35
Project: Research project
-
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Thenappan, T. (PI) & Reding, M. T. (Prior Principal Investigator)
3/20/24 → 3/19/33
Project: Research project
-
Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)
Reding, M. T., Lalezari, S., Kenet, G., Di Minno, G., Ducore, J., Solms, A., Shah, A., Holme, P. A., Poulsen, L. H., Meijer, K., Simpson, M. & Mancuso, M. E., Mar 2025, In: Drugs in R and D. 25, 1, p. 89-98 10 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Recombinant factor VIIa: new insights into the mechanism of action through product innovation
Escobar, M. A., Hoffman, M., Castaman, G., Hermans, C., Mahlangu, J., Oldenburg, J., Percy, C. L., Reding, M. T., Shapiro, A. D. & Pipe, S. W., Jan 2025, In: Research and practice in thrombosis and haemostasis. 9, 1, 102670.Research output: Contribution to journal › Review article › peer-review
Open Access -
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Reding, M. T., Lalezari, S., Kenet, G., Di Minno, G., Ducore, J., Solms, A., Shah, A., Holme, P. A., Poulsen, L. H., Meijer, K., Simpson, M. & Mancuso, M. E., Sep 2024, In: Drugs in R and D. 24, 3, p. 359-381 23 p.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations -
Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
Reding, M. T., Álvarez-Román, M. T., Castaman, G., Janbain, M., Matsushita, T., Meijer, K., Schmidt, K. & Oldenburg, J., Feb 2024, In: European Journal of Haematology. 112, 2, p. 286-295 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII
Reding, M. T., Simpson, M., Ducore, J., Holme, P. A., Maas Enriquez, M. & Mancuso, M. E., Apr 23 2024, In: Acta Haematologica. 148, 1, p. 58-67 10 p.Research output: Contribution to journal › Article › peer-review
Open Access